FindTrial
Sign In

INCAGN01876

DRUG7 trials

Sponsors

Incyte Biosciences International Sàrl, European Organisation for Research and Treatment of Cancer - EORTC, University of Pennsylvania, Providence Health & Services

Conditions

Advanced MalignanciesCancer of the Head and NeckCarcinoma, Squamous Cell of Head and NeckGlioblastomaMetastatic CancerMetastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma

Phase 1

A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors
CompletedNCT02697591
Incyte Biosciences International SàrlAdvanced Malignancies, Metastatic Cancer
Start: 2016-06-20End: 2019-12-16Updated: 2021-02-26
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
CompletedNCT03126110
Incyte Biosciences International SàrlAdvanced Malignancies, Metastatic Cancer
Start: 2017-04-25End: 2021-11-09Updated: 2025-08-14
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
TerminatedNCT03277352
Incyte Biosciences International SàrlAdvanced Malignancies, Metastatic Cancer
Start: 2017-11-21End: 2020-07-01Updated: 2021-07-22
Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC
RecruitingNCT04470024
Providence Health & ServicesCancer of the Head and Neck
Start: 2021-08-05End: 2027-12-31Target: 56Updated: 2025-07-10

Phase 2

Biomarker-based Study in R/M SCCHN
NCT03088059
European Organisation for Research and Treatment of Cancer - EORTCCarcinoma, Squamous Cell of Head and Neck
Start: 2017-11-16End: 2025-12-31Target: 340Updated: 2023-11-03
Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma
Active, not recruitingNCT04225039
University of PennsylvaniaGlioblastoma
Start: 2020-06-23End: 2029-04-30Updated: 2025-08-15
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
WithdrawnNCT05359692
Incyte Biosciences International SàrlAdvanced Malignancies, Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Start: 2023-03-01End: 2025-01-11Updated: 2023-09-15

Related Papers

First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors.
2025-10-01
Data from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
2025-10-01
Personalized biomarker-based treatment strategy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Results of the biomarker-driven cohorts of the EORTC-HNCG-1559 trial (UPSTREAM).
Journal of Clinical Oncology2025-05-28
Abstract CT112: An off-the-shelf multivalent vaccine containing cancer’s dark matter, DPV-001, combined with PD-1 +/- GITR in head & neck cancer: safety, efficacy, and immunodynamics from the phase 1 GITRVax trial
Cancer Research2024-04-053 citations
680 Multi-parametric assessment of the immune response to a trio immunotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma
Regular and Young Investigator Award Abstracts2023-10-31
PD1 inhibition and GITR agonism in combination with fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma: A phase 2, multi-arm study.
Journal of Clinical Oncology2023-06-017 citations
A phase 1/2 study of the safety, tolerability, and preliminary efficacy of the anti-GITR monoclonal antibody, INCAGN01876, combined with immunotherapies (IO) in patients (Pts) with advanced cancers.
Journal of Clinical Oncology2023-06-011 citations
Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).
Journal of Clinical Oncology2023-06-01
Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer
Future Oncology2023-05-185 citations
Abstract CT123: Trial in progress: First-in-human immunotherapy-trio for advanced head and neck squamous cell carcinoma
Cancer Research2023-04-14
677 A phase 2, open-label, multicenter study of INCAGN01876 (anti-GITR agonist) in combination with retifanlimab (anti–PD-1) in recurrent or metastatic head and neck squamous cell carcinoma
Regular and Young Investigator Award Abstracts2022-11-01
Abstract CT502: Preliminary immunological monitoring of first-in-human immunotherapy-trio for advanced head and neck squamous cell carcinoma
Cancer Research2022-06-15
443 An immunotherapy trio in advanced HNSCC for coordinated B and T cell antigen response
Regular and Young Investigator Award Abstracts2020-11-01
Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.
2018-12-0150 citations
Abstract 2714: Combination of monalizumab and durvalumab as a potent immunotherapy treatment for solid human cancers
Cancer Research2018-07-016 citations
EORTC 1559-HNCG: A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)—"UPSTREAM".
Journal of Clinical Oncology2018-05-202 citations
Abstract 3643: INCAGN1876, a unique GITR agonist antibody that facilitates GITR oligomerization
Cancer Research2017-07-013 citations